Allogene Therapeutics, Inc. (ALLO) vs Prime Medicine, Inc. (PRME)

Allogene Therapeutics, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Prime Medicine, Inc. are of similar size ($609.4M and $594.2M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against −17.9%. Allogene Therapeutics, Inc. has the higher net margin (−3,517.4% vs −4,613.1%) and the lower return on invested capital (−108.8% vs 0.00%). Across the 15 metrics below, Allogene Therapeutics, Inc. leads on 12 and Prime Medicine, Inc. on 3.

Valuation

Metric ALLO PRME Biotechnology median
P/E n/m n/m 7.88
P/S 115.35 126.19 11.47
P/B 1.24 12.91 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 44.66 102.84 10.73
Earnings yield (40.61%) (37.01%) (28.84%)
Free cash flow yield (18.90%) (30.52%) (23.03%)

Profitability

Metric ALLO PRME Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (3,832.45%) (4,824.94%) 0.00%
Net margin (3,517.41%) (4,613.11%) 0.00%
Free cash flow margin (2,180.62%) (3,850.92%) 0.00%
Return on equity (42.39%) (373.29%) (57.72%)
Return on assets (32.43%) (71.16%) (49.22%)
Return on invested capital (108.81%) 0.00% 0.00%

Growth

Metric ALLO PRME Biotechnology median
Revenue growth (TTM) 7,613.11% (17.90%) 5.64%
EPS growth (last fiscal year) 34.09% 18.18% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALLO PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.72 3.05 4.73
Net debt to EBITDA 1.24 0.88 0.96

Dividend

Metric ALLO PRME Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ALLO PRME Biotechnology median
Market cap 594.24m 609.43m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack